Fortrea price target raised to $13 from $11 at Mizuho

Mizuho analyst Ann Hynes raised the firm’s price target on Fortrea (FTRE) to $13 from $11 and keeps a Neutral rating on the shares as part of its 2026 outlook for managed care and health facilities. The firm believes 2026 will be a “pivotal year” for managed care. The sector is at the end of a three-year negative underwriting cycle and margins should improve in commercial, Medicaid and Medicare over the next few years, the analyst tells investors in a research note. As a result, Mizuho is positive on managed care heading into 2026.